Exhibitors

At the 35th International Symposium on ALS/MND we have a number of exhibitors who will be showcasing information both on the virtual platform and in Montreal. Find out more below:

LifeArc is a self-funded, not-for-profit medical research charity. We take science ideas out of the lab and help turn them into medical breakthroughs that can be life-changing for patients. We have been doing this for more than 25 years and our work has resulted in five licensed medicines, including drugs to treat cancer and Alzheimer’s, and a diagnostic for antibiotic resistance. LifeArc’s Motor Neuron Disease Translational Challenge is focused on accelerating healthcare innovation for people living with MND/ALS. Find out more about LifeArc and its work in motor neuron disease at www.lifearc.org.

Alamar Biosciences offers automated, high throughput solutions for ultra-high sensitivity protein biomarker analysis across a range of multiplex levels in liquid biopsy samples. With best-in-class attomolar sensitivity and up to 12-log dynamic range, our revolutionary technology is powering precision proteomics to enable the earliest detection of disease.

ARG is the leading ALS-focused CRO, offering comprehensive clinical program development services. Since 2004, we’ve been dedicated to advancing neurodegenerative research, supporting all phases of ALS trials. With deep expertise and global relationships with leading sites and investigators, we provide flexible, personalized services tailored to each sponsor’s unique needs. At ARG, we drive clinical development with a commitment to improving lives—because everyone deserves to be well.

Axol Bioscience is working with urgency to improve in vitro models to support ALS drug discovery. With over 10 years’ experience, Axol manufactures high quality functional cells derived from iPSCs from ALS and unaffected donors. With a new suite of ALS related cells including motor neurons and microglia and a full out-sourced service capability we look to support and de-risk ALS research and drug discovery.

Corcept Therapeutics is a commercial-stage pharmaceutical company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. For more than 25 years, Corcept’s singular focus on cortisol modulation has led to the discovery of more than 1,000 proprietary selective cortisol modulators that have the potential to deliver improved patient outcomes across a wide range of diseases. Corcept is headquartered in Redwood City, California. For more information, visit Corcept.com.

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. Our mission is to reimagine the future of medicine by delivering innovative cures that transform lives. We are leveraging our modular and validated technology platform to advance a pipeline of proprietary gene therapies for the treatment of patients with ALS-SOD1, Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases.

Wyes is a deep tech startup dedicated to improving the lives of individuals with neurodegenerative diseases. By creating accessible devices, we empower users to communicate effortlessly with their loved ones, caregivers, and society—and even regain full online access, all with just the blink of an eye.